Welcome to HealthcareBanker.com

Thank you for visiting HealthcareBanker.com a news aggregator of middle-market mergers and acquisition activity in the healthcare industries. This site addresses investment banking topics dealing with M&A, Capital Raising, Borrowing/Lending and other Corporate Development and Finance activities within the Healthcare Services, Healthcare IT, Medical Device, and Life Science industries.

Tuesday, June 23, 2015

Making it Rain on the LIfe Sciences

#BIO2015: What life sciences sectors are ripe for M&A?


(from MedCity News)

In this bullish life sciences market, which sectors are most ripe for acquisition? Which assets will have a tougher time to sell?

A report, released at this week’s BIO International Convention in Philadelphia by management consultancy Campbell Alliance, laid out a number of interesting insights on the M&A environment in the life sciences. Study author Neel Patel discussed the results.

Telemedicine Going Mainstream

Teladoc’s IPO telegraphs telemedicine’s prime-time debut

(from VentureBeat)

Teladoc CEO Jason Gorevic is now on the road talking to institutional investors about his company’s upcoming IPO, a Teladoc spokesperson told VentureBeat Monday. Many will be watching the Teladoc CEO with interest to see if Wall Street is truly warming up to digital health companies.

Teladoc filed (private) documents for its public offering in late April, but have yet to announce an official date for the outing. A public S-1 appeared in early June, stating that the company hopes to raise $137 million.

Wednesday, June 17, 2015

Must read White Paper on Private Placements in the Life Sciences Industry.



WHITE PAPER RELEASE: Private Placements in the Life Sciences Industry

(from OfferBoard)

For many life science startups, traditional funding sources, like federal and university grants, can be difficult to obtain and often only cover a portion of administrative, research and development expenses. As a result, equity crowdfunding has become an interesting and viable fundraising alternative. Offerboard’s research team recently published its inaugural white paper on fundraising activity in life sciences industry , as reported through the end of the 2014 calendar year.

Monday, June 15, 2015

Corporate Venture Capital 101 For Life Sciences


Statement of Strategics in Life Sciences

(from Lake Whillans)

For healthcare startups seeking private investment, there are more sources than ever. But there is also more peril. Traditional routes, like venture capital and angel investors, are joined by corporate venture capital, a broader array of grant opportunities, venture philanthropy, crowdfunding and beyond.

Corporate venture capital has become particularly popular. But there isn't as much critical information about corporate investors and their strategies. Which is the most trustworthy? Which is the best to partner with? Which one would you never do a deal with again? We believe that the answers to these questions can be critical to the success of a growing business; the right partner can provide synergies and non cash resources to catapult the business to success, while the wrong partner might swipe critical IP that entangles a company in litigation.

Friday, June 12, 2015

Follow the Leader - Who is Taking Charge in Healthcare Startup Investments

A growing problem for healthcare startups seeking investment: (Almost) no one wants to lead

(from MedCity News)

It’s early on at today’s Redefining Early Stage Investments (RESI) Conference in Houston. But here’s one phrase I’ve already heard too often: We don’t lead. Anyone in any sector that’s tried to raise capital has heard that phrase — sometimes for good reasons. But it’s going to be heard too often as healthcare investing continues to evolve. Healthcare needs leaders.

More and more corporate venture capitalists won’t lead, for example. Yet, in many cases, they ask an awful lot from a startup. A Shire representative told attendees in Houston that Shire invests largely to acquire, will look to acquire the technology but not the whole company, and won’t lead. That’s not ideal for an early-stage company, which would prefer to keep its M&A options open.

Thursday, June 11, 2015

Should Physicians Invest in Private Placements to Diversify Portfolio?

As an investment banker that specializes in the healthcare industry and who has consulted with over a thousand physicians, I can understand their apprehension when it comes to investing in opportunities that are not generally available to the public, in this case private placements. The notion of investing in an opportunity that seems “exclusive” with the potential for extraordinary returns can lead someone to believe that if it sounds to good to be true then it must be, particularly among physicians who are used to being courted all the time by third parties interested in their business.

However, while it is necessary for anyone who is considering investing in a private placement to conduct a thorough due diligence on the offering, I also think that physicians who qualify as accredited investors shouldn’t discount private placements as a viable way to diversify their portfolios, particularly if its in an area in which they may have some knowledge or professional interest in such as medical device companies or bio-techs that are starting up or looking to grow and require capital. My feeling is that if a physician were presented with an investment opportunity in a business with which they can relate to, they may be more inclined to take on some risks if doing so meant bringing to market a product or service that could benefit their patients or the healthcare community at large, while providing a nice return on their investment.

Here is a link to an interesting article on Using Private Placements As a Component of Your IRA Portfolio...